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Abstract
Background: The emergence of drug resistance is a major problem in malaria control. Combination of molecular
genotyping and characterization of mutations or single nucleotide polymorphisms (SNPs) correlated with drug
resistance can provide information for subsequent surveillance of existing and developing drug resistance patterns.
The introduction of artemether/lumefantrine (AL) as first-line treatment, never used before in Ethiopia, allowed the
collection of baseline data of molecular polymorphisms before a selection due to AL could occur.
Method: 97 patients with uncomplicated falciparum malaria were recruited from April to June 2006 and treated
with either AL, quinine (Q) or atovaquone/proguanil (AP) in Jimma University Hospital, Ethiopia. Mutations or SNPs
associated with resistance to these drugs were analysed by RFLP (pfdhfr, pfmdr1) and sequencing of the target
genes (pfcytb, pfserca ).
Results: SNPs previously reported to be associated with resistance to the study drugs were identified in
recrudescent and treatment sensitive isolates. A total of seven recrudescences were obtained. The pfmdr1 N86Y
mutation was found in 84.5% of isolates. The triple mutation 51I,59R,108N of the pfdhfr gene occured in high
frequency (83.3%) but no pfcytb mutation was detected. Sequencing showed a variety of previously described and
new mutations in the pfserca gene.
Conclusion: The prevalence of mutations was in accordance with the expected patterns considering recent drug
regimens. The broad introduction of AL and the cessation of former drug regimens might probably change the
current distribution of polymorphisms, possibly leading to decreased sensitivity to AL in future. Continuous
surveillance of molecular patterns in this region is, therefore, recommended.
Background
Malaria is still one of the leading health problems in our
time. Most cases and deaths occur in Sub-Saharan
Africa. Malaria is endemic in large parts of Ethiopia
including the town of Jimma and its surroundings with
most cases occurring from September to December and
April to June during and after the rainy seasons [1].
High levels of drug resistance of Plasmodium falciparum
strains against anti-malarials, first chloroquine and later
sulphadoxine/pyrimethamine (SP), resulted in new drug
policies in Ethiopia. In 2004, the first-line treatment
recommendation was switched from SP to artemether-
lumefantrine (AL), an artemisinin-based combination
therapy (ACT) [1-3]. Due to a shortage in supply, Qui-
nine was used for several months instead. AL was intro-
duced by the underlying study in this region. ACT
combines the potential of rapid reduction of the parasite
burden and elimination of remaining parasites due to
longer-acting partner drugs [4]. The correlation between
distinct SNPs and anti-malarial drug resistance or clini-
cal outcome has been widely discussed. Mutations in
the Plasmodium falciparum multi-drug resistance
(pfmdr1) gene have been associated with resistance to
chloroquine, quinine, mefloquine, lumefantrine and
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artemisinin [5-8]. Increased sensitivity to (Dihydro-)
Artemisinin in the presence of wild type codon 86 in
pfmdr1 and in vivo selection of pfmdr 86N during AL
treatment has been reported [9-12].
The target structure for artemisinins was first
described by Eckstein et al in 2003, abandoning other
theories about the mode of action. PfATP6, a SERCA-
type ATPase (pfserca) of P. falciparum, is inhibited by
artemisinins [13]. An L263E replacement and other
mutations decreased sensitivity to artemisinins [14].
Since then, further resistance-related mutations con-
cerning artemisinins have been detected in laboratory
strains and field isolates associated with in vitro resis-
tance [15-17]. Recent reports about high in vivo toler-
ance of artemisinin-based combination therapy (ACT)
and artesunate monotherapy in Cambodia and Thailand
are all the more alarming [18-20].
In this study, polymorphisms related to drug resis-
tance were investigated. Mutations of the genes pfmdr1
(codon 86) and pfdhfr (codon 16, 51, 59, 108, 164), the
latter associated with proguanile resistance, were ana-
lyzed by RFLP. Regions in the pfserca and Plasmodium
falciparum cytochrome B (pfcytb) gene related to arte-
mether and atovaquone resistance, respectively, were
sequenced.
Methods
Study area and population
The study was performed at the Jimma University (JU)
Hospital in the city of Jimma, 1,700 m above sea level
and 335 km south west of Addis Ababa, Ethiopia.
Patients over five years of age (mean 19.1, range 6-50)
with parasitologically proven uncomplicated falciparum
malaria were recruited from April until June 2006. Writ-
ten consent was obtained from either the patient or a
parent/legal guardian. The study was conducted conco-
mitantly with the previous published work on ototoxicity
of artemether/lumefantrine in comparison with quinine
and atovaquone/proguanil and was approved by the
Jimma University Ethical Committee and is registered
with Clinical Trial.gov, Number NCT00451139 [21].
Procedures
Blood samples were obtained at days 0, 7 and 28 as well
as on any day until day 90 in case of re-occurrence of
symptoms suggesting malaria [22]. Aliquots of 10 μl of
capillary blood were spotted to Whatman 3 MM Chr fil-
ter paper, air dried, and stored at ambient temperature
for later molecular analysis. The definition of the treat-
ment outcome followed the WHO draft protocol for
areas with low or moderate malaria transmission [2].
Parasite DNA was extracted from blood spots on the
filter paper by the Chelex method [23]. The species was
identified by nested polymerase chain reaction (PCR)
[24]. Single and multiple clone infections from day 0
were determined by amplification of msp1 and msp2
genes. To distinguish between re-infection and recrudes-
cence, genotyping by amplification of msp1, msp2 and
enzymatic digestion (RFLP) of the PCR products was
performed between the pair of samples [25].
To amplify the pfmdr1 and pfdhfr gene, a nested PCR
was used, the polymorphisms were detected by RFLP
[26,27]. The PCR products were separated in 2% agarose
gels stained with ethidium bromide and visualized under
UV light. The regions of interest of the pfcytb and the
pfserca gene were amplified by established PCR proce-
dures [28,29]. The amplified gene fragments were puri-
fied from gel using Ultrafree-DNA extraction kit. Cycle
sequencing was done with the BigDye Terminator Cycle
Sequencing Kit and products analysed on the ABI3730
sequencer. Primers used for sequencing were those from
the PCR. Sequences were verified using templates from
two independent amplifications of the same DNA sam-
ple. Sequencing analysis was performed from both direc-
tions for each template. Sequences were analysed using
the programme Bioedit and the NCBI blast function for
comparison with sequences published in the GenBank
database. (Reference strain for pfserca: Dd2, accession
number: AB121053 and 3D7, acc no.: AL844501.1; for
pfcytb: 3D7, acc. No.: AF069605)
Results
97 patients were included in the study with 30 patients
receiving AL, 35 Q, and 32 AP. Clinical and parasitolo-
gical efficacy as well as baseline data were described
elsewhere in detail [21]. No treatment failure occured
before or on day 7 in any treatment group. Until day 28,
three patients in the Q group and two in the AP group
presented with PCR-confirmed recrudescent falciparum
malaria. Later, one recrudescence was detected in a
patient in the Q group on day 40, and possibly another
on day 70 in the AL group (Table 1).
The overall prevalence of pfmdr1 mutations was high
(84.5%) (Table 2). In the Q group, all four treatment
failures showed the pfmdr1 mutation at codon 86Y, but
also 90.0% of the clinical sensitive samples presented
with the mutation. In the AL group, four samples
showed the wild type, one mixed (wild type and muta-
tion); the remaining 25 samples exhibited only the
mutation.
The expected high prevalence of the polymorphisms
at codons 51I, 59R, and 108N of the pfdhfr gene was
found. Both recrudescent strains in the AP group
showed the triple mutations (51I, 59R, 108N). The only
A16V mutation in the AP group was found in the clini-
cal symptomatic treatment failure (Table 1).
The pfserca gene was amplified and sequenced from
the codons 230 to 463 and 600 to 790. Sequencing was
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intended for all 30 AL samples including the recrudes-
cent strain, amplification failed due to long storage con-
ditions of the DNA and general problems with these
particular PCRs for the day 0 counterpart of the one
possible recrudescent sample on day 70 and for many
PCRs with the ATP1 and ATP2 primers. All gained
sequences could be identified as part of the pfserca gene
with the reference strain Dd2. 12 mutations or SNPs
were identified, six new and six described. The pre-
viously reported E431K mutant codon was the most fre-
quent occurring in seven isolates [29,30]. Each of the
other genotypes was detected only once. No sample
showed more than two mutations. Three of the new
mutations were non synonymous and the other three
synonymous (Tables 3 and 4). The sample from day 70
yielded no mutation in the pfserca gene.
No mutations were detected in the amplified regions
of the pfcytb gene of 2 recrudescent strains in the AP
group.
Discussion
High cure rates of AL have also been reported from
other recent studies with 28 days of follow-up in Ethio-
pia [31,32]. For the detection of late recrudescences,
follow-up periods longer than 28 days seem more
appropriate. In this study, genotyping indicated a recru-
descence on day 70 in one patient treated with AL. The
msp-1 gene and especially the RFLP results with
different enzymes (Hinf III, Dde I, Rsa I) of the msp-2
gene showed the same molecular pattern for the two
samples from day 0 and day 70 [25]. Additionally, a
short sequence of the msp-1 gene was amplified, as the
amplification of the pfserca sequence failed. The two
sequences fully matched, blasting showed a difference
between the Ethiopian sequence and other published
strains from different regions of 90-96% [33]. Though,
re-infection with a very similar clone not to be differen-
tiated by molecular methods is still possible regarding
the moderate transmission area. This particular molecu-
lar RFLP pattern was found in almost a quarter of all
samples. Overall, at least six different patterns in differ-
ent combinations, four being predominant, were
observed. (Data not shown) The two particular samples
from day 0 and day 70 showed the tyrosine mutation at
codon 86 of the pfmdr1 gene.
Table 1 Clinical and parasitological treatment failures
PCR-corrected failure rates* AL Q AP
Number of patients with recrudescence/total number of patients
(day)
1/30 (70)** 4/35 (24, 28, 28,
40)
2/32(28, 28)
Drug resistance associated polymorphisms 1. pfserca gene
2. pfmdr codon 86N
1. pfmdr codon
86N
1. cytb gene codon 268
2. dhfr triple mutation (51I+59R
+108N)
3. dhfr codon A16V
Polymorphisms in recrudescent samples n (%) 1. 0 (0)
2. 0 (0)
1. 0 (0) 1. 0 (0)
2. 2 (100)
3. 1 (50)
*P. falciparum: Genotyping by PCR and RFLP patterns of the msp-1 and msp-2 gene
**Possible Recrudescence
Table 2 Prevalence of pfdhfr and pfmdr1 mutations
Genetic
Polymorphism
Overall prevalence rate mutation/total n
(%)
DHFR A16V 1/97 (1.1)
DHFR N51I 83/84* (98.8)
DHFR C59R 85/97 (87.6)
DHFR S108N 97/97 (100.0)
DHFR S108T 0/97 (0.0)
DHFR (51I,59R,108N) 70/84 (83.3)
DHFR I164L 0/97 (0.0)
pfmdr N86Y 82/97 (84.5)
*RFLP outcome not distinguishable for 13 samples






E237A 6/7 (85.7) 1/7 (14.3)
H243Y 7/7 (100.0) 0/7 (0.0)
L263E 7/7 (100.0) 0/7 (0.0)
L263L 6/7 (85.7) 1/7 (14.3)
L402V 14/15 (93.3) 1/15 (6.7)
E431K 5/12 (41.7) 7/12 (58.3)
N460N 12/12 (100.0) 0/12 (0.0)
A623E 23/24 (95.8) 1/24 (4.2)
A630S 23/23 (100.0) 0/23 (0.0)
R682R 22/23 (95.7) 1/23 (4.4)
N683E 22/23 (95.7) 1/23 (4.4)
N683K 22/23 (95.7) 1/23 (4.4)
K766K 26/27 (96.3) 1/27 (3.7)
K767E 26/27 (96.3) 1/27 (3.7)
K767R 26/27 (96.3) 1/27 (3.7)
S769N 26/27 (96.3) 127 (3.7)
K771E 25/25 (100.0) 0/25 (0.0)
K776N 24/24 (100.0) 0/24 (0.0)
Fragments spanning codons 230 to 463 and 600 to 790, respectively, ref. [29])
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The previously described mutant codon S769N being
associated with in vitro resistance in French Guiana was
found in a clinical sensitive sample [15,17]. Other
recently published mutations were not detected in the
amplified regions of the study samples but the pfserca
gene was only partly sequenced for 31 samples [34].
Overall, 12 different mutations were observed in an AL-
naive population, some of these mutations seem to be
globally distributed as reports from Asia and South
Africa indicate and not to be associated with drug resis-
tance or caused by drug pressure [34]. The next step
will be the comparison of the polymorphisms in these
isolates with about 350 P. falciparum samples, recently
collected in Jimma area. Almost four years after the
broad introduction of AL in Ethiopia, selection or disap-
pearence of certain mutations may have occured.
A study conducted in southern Ethiopia prior to the
introduction of ACTs showed a prevalence of pfmdr1
86Y of 81% and of the mutant pfcrt 76 of 100% [35].
High prevalence rates of the pfmdr1 mutation 86Y were
therefore expected. Q has been used for decades in
Ethiopia as second line treatment and treatment for
severe malaria, treatment failures occured sporadically.
Exact data were not published. Due to intensive use in
Thailand for example, failure rates with Quinine raised
dramatically. Attempts to show a clear correlation of
drug resistance with molecular patterns has failed so far,
mutations in the pfmdr1 gene were discussed [36]. All
treatment failures in the Q group showed the SNP of
pfmdr 86Y associated with chloroquine resistance but
increased sensitivity to quinine in in vitro studies. No
selection to 86N in the recrudescent samples was
observed but the small sample size and few treatment
failures allow no conclusions [37].
The high prevalence of dhfr mutations is likely caused
by wide use of proguanil, active metabolite of sulpha-
doxine/pyrimethamine, prior to AL introduction in the
area. In the above cited study from Ethiopia, the pfdhfr
mutations N108, I51 and R59 were present in 100%,
97% and 90%, respectively, of all investigated samples,
the pfdhfr triple mutations (51I+59R+108N) occurred in
87% of the isolates [35]. Another study from Jimma
reported 100% prevalence of the 108N and 51I muta-
tions, and 54% prevalence of the pfdhfr triple mutation
[38]. The occurrence of the triple mutations in both
recrudescent isolates of the AP group was therefore very
likely. Nevertheless, the idea of these mutations being a
necessary but not sufficient cause of resistance to pro-
guanil is supported. The circumstance that the only
mutation at codon A16V occurred in the recrudescent
sample may have contributed at least to the late treat-
ment failure at day 28.
Although the combination AP has never been broadly
used in the study region before, it simply served as
negative control in the ototoxicity trial, two parasitologi-
cal failures occurred, one was clinical symptomatic.
Treatment failures have been reported from Africa.
Some have been associated with mutations in the cytb
gene, since in vitro resistance to AP was correlated espe-
cially with mutations at codon 268 of that gene [39-41].
A molecular survey from Ethiopia and Gabon detected
no mutations in the pfcytb gene of samples from Ethio-
pia but several different mutations in 10% of Gabonian
samples, although AP was not in use in both regions
[42]. Spontaneous mutations are rare but seem to
occure independent from drug pressure. Both recrudes-
cent isolates in this study showed no mutations in the
amplified sequence containing codon 268 but not the
whole gene was sequenced and other mutations are pos-
sible. Treatment failures may also be due to limited
bioavailability in some patients. However, as AP is
highly recommended as prophylaxis for travellers to
Ethiopia, a failure rate of 6.3% was quite alarming.
Conclusion
As expected, there were no signs of clinical or parasito-
logical failures in the AL group except for one possible
very late recrudescence on day 70 at the time of ACT
introduction. The patterns of mutations in general fit
with the situation of long-lasting chloroquine and SP
usage before the presence of ACT in this area. Q is the
national second-line treatment and backup, however its
use will be compromised by the degree of resistance
Table 4 List of pfserca non synonymous and synonymous
mutations found
Nucleotide mutation amino acid
(NS; Syn)
No. of mutations Reference
A709C E237A 1 New
C726T H243Y 0 29
T787G, T788A L263E 0 29
A789G L263L 1 New
1204G L402V 1 29
G1291A E431K 7 29
T1380C N460N 0 30
C1867A A623E 1 29
G1887T A630S 0 29
A2045G R682R 1 New
A2046G, T2048A N683E 1 29
T2048A N683K 1 30
A2297G K766K 1 New
A2298G K767E 1 New
A2299G K767R 1 New
G2305A S769N 1 29
A2310G K771E 0 29
G2327T K776N 0 29
Fragments spanning codons 230 to 463 and 600 to 790, respectively, ref. [29])
Eshetu et al. Malaria Journal 2010, 9:226
http://www.malariajournal.com/content/9/1/226
Page 4 of 6
shown in our results. AL seems to be the best treatment
option and must be available consistently. Moreover
continuous surveillance should be established in the
area for AL as data from South East Asia showed
decreased susceptibility of P. falciparum for ACT several
years after introduction. A similar development could
possibly be expected in Ethiopia.
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